. The similarity between the molecular findings of ketamine and (2R,6R)-HNK led us to re-examine the potential involvement of (2R,6R)-HNK in NMDAR function.
We assessed the effects of (2R,6R)-HNK in NMDAR-mediated miniature excitatory postsynaptic currents (NMDAR-mEPSCs) in cultured hippocampal neurons and compared its properties to the NMDAR antagonists 2R-amino-5-phosphonopentanoate (AP5) and ketamine. NMDA-mEPSCs were isolated in the presence of , n = 8, P = 0.0018; 50 μ M (R,S)-ketamine, n = 9, P < 0.0001; 10 μ M (2R,6R)-HNK, n = 9, P = 0.1606, 50 μ M (2R,6R)-HNK, n = 9, P = 0.0051). f, The percentage of reduction of NMDAR activity after application of compounds (one-sample t-test: DMSO, P = 0.3248; 50 μ M AP5, P < 0.0001; 50 μ M (R,S)-ketamine, P < 0.0001; 10 μ M (2R,6R)-HNK, P = 0.1349; 50 μ M (2R,6R)-HNK, P = 0.0011). g, Western blots for phosphorylated eEF2 (p-eEF2) and total eEF2 following treatment with 50 μ M (R,S)-ketamine, 10 or 50 μ M (2R,6R)-HNK, or DMSO for 30 min. The ratio of p-eEF2 to total eEF2 was normalized to DMSO. 50 μ M (R,S)-ketamine and 50 μ M (2R,6R)-HNK significantly decrease p-eEF2 (one-sample t-test: 50 μ M (R,S)-ketamine, P < 0.0001, n = 7; 10 μ M (2R,6R)-HNK, P = 0.3027, n = 8; 50 μ M (2R,6R)-HNK, P = 0.0330, n = 8).
tetrodotoxin (TTX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and picrotoxin to suppress both activity and AMPAR-and GABAreceptor-mediated neurotransmission. NMDA-mEPSCs were enhanced by removal of extracellular Mg 2+ (refs 6, 7) . Under these conditions, baseline NMDA-mEPSCs were recorded for 6 minutes, then either 50 μ M AP5, 50 μ M (R,S)-ketamine, or 10 μ M or 50 μ M (2R,6R)-HNK, were perfused into the bath for 3 min and recording continued for a further 10 min. Charge transfer was determined before and after treatment as a measure of NMDAR blockade. The potent NMDAR antagonists AP5 and (R,S)-ketamine produced a significant decrease in NMDAR charge transfer compared to vehicle treatment (Fig. 1a-c, f) , in agreement with previous data 7 . Whereas 10 μ M (2R,6R)-HNK did not alter NMDA charge transfer (Fig. 1d, f) , 50 μ M (2R,6R)-HNK produced up to a 40% decrease (Fig. 1e, f) , demonstrating that (2R,6R)-HNK significantly inhibits NMDAR currents at rest.
We examined whether the dose-dependent effects of (2R,6R)-HNK on NMDAR inhibition extended to intracellular signalling. We treated hippocampal cultures with 50 μ M (R,S)-ketamine or 10 μ M or 50 μ M (2R,6R)-HNK and analysed the levels of phosphorylated eEF2 (Fig. 1g) . Congruent with our electrophysiology data, 50 μ M (2R,6R)-HNK, but not 10 μ M (2R,6R)-HNK, resulted in a significant decrease in phosphorylated eEF2 levels (Fig. 1g) . These data are consistent with those in ref. 2 , demonstrating that (2R,6R)-HNK significantly decreased eEF2 phosphorylation in hippocampal synaptoneurosomes and indicating that (2R,6R)-HNK decreases eEF2 phosphorylation by inhibiting NMDARs at rest.
To ascertain further the mechanism by which (2R,6R)-HNK inhibits NMDAR currents, we analysed the properties of individual NMDAmEPSCs. Application of 50 μ M (R,S)-ketamine fully blocked and nearly abolished NMDA-mEPSCs (Fig. 2a) , whereas 50 μ M (2R,6R)-HNK only partially impaired NMDAR-mEPSCs (Fig. 2b) . In cumulative probability plots, 50 μ M (2R,6R)-HNK produced a significant leftward shift towards smaller amplitudes of NMDA-mEPSCs compared to baseline, consistent with a postsynaptic effect (Fig. 2c) . The evaluation of the decay and rise times of NMDA-mEPSCs before and after (2R,6R)-HNK revealed that the metabolite facilitated the decay times of individual NMDA-mEPSCs without a significant change in rise times, indicating that (2R,6R)-HNK acts as an open-channel NMDAR blocker similar to ketamine and MK-801 (ref. 6) ( Fig. 2d-g ).
Ketamine is metabolized in the liver. Intraperitoneally administered drugs, the route used by Zanos et al., are absorbed mainly through the portal vein and, as a consequence, pass through the liver and are exposed to initial metabolism before reaching the systemic circulation and, subsequently, the brain 8 . In clinical studies assessing the antidepressant effects of ketamine, the drugs were administered intravenously using a bolus. Thus, intraperitoneal administration of ketamine to laboratory animals may exacerbate/exaggerate the contribution of metabolites to the antidepressant-like effects. Moreover, as recently shown 9, 10 , the enantiomer S-ketamine, which is metabolized to (2S,6S)-HNK and not (2R,6R)-HNK, possesses a clinical antidepressant effect, with a similar potency to that of racemic ketamine 11 . This is notable as its metabolite is substantially less active than (2R,6R)-HNK in preclinical studies, thus arguing against a substantial contribution of specific metabolites to antidepressant responses in patients. Of note, direct application of ketamine to cultured neurons or brain slices inhibits NMDAR and deactivates eEF2K, triggering an AMPAR-dependent form of synaptic potentiation linked to rapid antidepressant action similar to that observed in vivo, which substantiates the conclusion that inhibition of NMDARs is responsible for the synaptic and BRief COmmuniCATiOns ARising antidepressant effects of ketamine [3] [4] [5] . Although it is shown in ref. 2 that (2R,6R)-HNK can produce antidepressant-like effects, it is also shown that deuterated ketamine at the C6 position (6,6-dideuteroketamine), which is not expected to alter its NMDA-binding affinity but slows its metabolism, nevertheless produces a rapid antidepressant effect within 1 hour of administration but not after 24 hours, suggesting that NMDAR inhibition triggers rapid antidepressant efficacy, and (2R,6R)-HNK-mediated antidepressants effects are possibly driven by continued NMDAR inhibition.
The finding that (2R,6R)-HNK inhibits NMDARs may seem unexpected, as binding data shows that an affinity greater than 100 μ M is required to displace [ 3 H]MK-801 (ref. 12). However, it is possible that low-affinity binding of (2R,6R)-HNK may involve additional binding sites on the NMDAR that do not overlap with high-affinity MK-801 binding, as previously shown for memantine 13 . The ability of a compound to displace binding of an open-channel blocker such as MK-801 does not necessarily reveal its full functional effect on NMDARs.
Our data demonstrating that (2R,6R)-HNK inhibits NMDAR at rest may seem at odds with that from ref. 2 , which reported that (2R,6R)-HNK does not block NMDARs 2 . However, in the previous study, the authors only examined a dose of 10 μ M (2R,6R)-HNK on hippocampal slices following a 30-sec pulse of NMDA, whereas our investigation directly measured synaptic NMDAR currents. We tested 10 μ M (2R,6R)-HNK, as well as a slightly higher dose, as the physiological concentration of the metabolite in the brain relevant to antidepressant effects is not well-established. The higher (2R,6R)-HNK concentration revealed that this compound has properties consistent with an open-channel blocker of NMDARs. The examination of only a single concentration of (2R,6R)-HNK, as well as testing the effect on NMDARs after NMDA application, probably account for the differences in (2R,6R)-HNK-dependent effects on NMDARs. Collectively, our findings show that (2R,6R)-HNK causes blocking of synaptic NMDARs similar to ketamine.
In summary, our data demonstrate that (2R,6R)-HNK inhibits synaptic NMDARs, which subsequently triggers intracellular signalling previously proposed to underlie the antidepressant effects of ketamine as well as (2R,6R)-HNK. These data argue against the premise that (2R,6R)-HNK acts in an NMDAR-independent manner and instead shows that (2R,6R)-HNK is an open-channel blocker of NMDARs. These data indicate that blocking NMDAR is the likely effect of (2R,6R)-HNK in antidepressant action. Ketamine has a relatively short half-life and yet can exert long-lasting antidepressant effects 2 . We propose that (2R,6R)-HNK, through inhibition of NMDARs, may explain the longer-lasting antidepressant effects of ketamine that are not observed by other NMDAR blockers.
Methods
The electrophysiological and biochemical techniques are described in the Supplementary Information. Data availability. All data are available from the corresponding author upon reasonable request. . Furthermore, our field-potential electrophysiology experiments were conducted in the presence of the NMDAR antagonist AP5 (80 μM), demonstrating that the AMPAR-mediated synaptic potentiation we observed is indepen dent of any capacity of (2R,6R)-HNK to inhibit the NMDAR.
Kanzo
We agree with Suzuki et al. that assessing higher concentrations of (2R,6R)-HNK on NMDAR-mediated miniature excitatory postsynaptic currents (NMDAR-mEPSCs) responses might be important in providing information for off-target effects of this metabolite, and their study indeed provides evidence for a modest inhibition (~ 37%) at the concentration of 50 μ M. The absence of Mg 2+ in the testing conditions may influence the apparent discrepancy between 37% inhibition of NMDAR-mEPSCs at the 50 μ M concentration (for example, as is the case with memantine, which only inhibits NMDAR-mEPSCs in the absence of Mg . Notably, we did not observe NMDAR-inhibitionassociated psychostimulant, self-administration, drug discrimination and pre-pulse inhibition side effects of (2R,6R)-HNK at any dose, including up to 375 mg kg −1 (ref.
2). The authors also observed decreased phosphorylation of the eukaryotic elongation factor 2 (eEF2) only at the concentration of 50 μ M. Although this is the same high concentration at which (2R,6R)-HNK induced an inhibition of the NMDAR responses, these data do not provide direct evidence of a functional link between the moderate inhibition of NMDARs and the decrease in eEF2 phosphorylation. Indeed there are multiple mechanisms other than NMDAR inhibition that could be responsible for the observed eEF2 dephosphorylation [5] [6] [7] [8] . It is also important to note that although direct application of ketamine 9 or the alternative NMDAR blocker MK-801 (ref. 10) to cultured neurons or hippocampal slices was previously reported to induce NMDAR-inhibition-dependent synaptic potentiation, MK-801 has repeatedly failed to induce ketamine-like sustained antidepressant effects in several animal tests 2, 9, 11, 12 . It is therefore probable that synaptic strengthening as a consequence of NMDAR inhibition (proposed by Suzuki et al.) is not solely responsible for the antidepressant actions of ketamine. Indeed, the results of clinical trials indicate that several other NMDAR antagonists lack the full antidepressant actions of ketamine in humans 13 . Suzuki et al. also propose that NMDAR inhibition by (R,S)-ketamine is responsible for the initiation of antidepressant responses (that is, the acute actions), and HNK metabolites mediate the longterm antidepressant effects of ketamine through continued NMDAR inhibition. This hypothesis is not supported by our pharmacokinetic measurements of ketamine and its metabolites in the brain of mice following intraperitoneal administration of (R,S)-ketamine, which show that both ketamine and its metabolites peak at similar early time points, have a similar short half-life, and are below detectable levels by four hours after treatment 2 . In conclusion, the data presented by Suzuki et al. further support an NMDAR-inhibition-independent mechanism of antidepressant action of the ketamine metabolite (2R,6R)-HNK at physiologically relevant concentrations. Although development of (2R,6R)-HNK as an anti depressant drug, which does not induce NMDAR-mediated side effects, can proceed independently of target identification, it remains important to identify its primary pharmacological target at anti depressant-relevant concentrations (~ 10 μ M).
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